Drugs / (2)-epigallocatechin-3-gallate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01357681 | Sep 2011 → May 2015 | Huntington disease | Charite University, Berlin, Germany | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (2)-epigallocatechin-3-gallate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01357681 ↗ |
| Known as | EGCG | “The green tea polyphenon (2)-epigallocatechin-3-gallate (EGCG) was shown to have beneficial effects in cell and animal models of HD.” NCT01357681 ↗ |
| Route | Oral | “Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600)” NCT01357681 ↗ |